Company intelligence / Profile preview

Novoic

London, England, United Kingdomnovoic.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Novoic has developed AI-powered software that analyzes audio-linguistic patterns in speech to detect early signs of neurodegenerative diseases such as Alzheimer’s and Parkinson’s. Their technology enables scalable, non-invasive screening for cognitive impairment using any smart device. The company has demonstrated accurate detection of mild cognitive impairment, including sub-threshold changes associated with preclinical Alzheimer’s disease. Active clinical validation programs are ongoing but no published pivotal trial results or regulatory approvals have been announced yet.

Therapeutic areas: PsychiatryNeurology
Modalities: Software-as-medical-device (SaMD)Non-pharmacological therapy (AI-enabled speech analysis)Digital biomarker platform
Industry: Digital Health Medical Devices

Beyond the preview

Go deeper on Novoic.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Novoic.

Explore the full profile